Nanjing King-friend Biochemical Pharmaceutical Co Ltd (603707 SHG) stock market data APIs

Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. engages in the research, development, production, and sale of pharmaceutical raw materials and preparations in China and internationally. The company offers generics for oncology, critical care, IVF, and diabetes; and standard heparin preparations and low molecular weight heparin preparations, including enoxaparin sodium injections, dalteparin sodium injection, and nadroparin calcium injection. It also provides non-heparin sterile injections, such as adalimumine injection, paclitaxel injection, liraglutide injection, daptomycin for injection, pantoprazole sodium for injection, reganoxone injection, leucovorin calcium for injection, bivalirudin for injection, micafungin for injection, ducalciferol injection, fondaparinux sodium injection, and cisatracurium besylate injection. In addition, the company offers process development and preparation, process optimization, registration and validation approval, and manufacturing, as well as customized research and development, and manufacturing for commercialization. Its injection products are used in anticoagulation, anti-tumor, and cardiovascular disease areas, surgical anesthesia, antibacterial infection, and contrast imaging. The company was founded in 2000 and is based in Nanjing, China.